Canada markets closed

Scorpius Holdings, Inc. (SCPX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.1800-0.0038 (-2.07%)
At close: 04:00PM EDT
0.1852 +0.01 (+2.89%)
After hours: 04:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1838
Open0.1790
Bid0.1797 x 1100
Ask0.1950 x 1100
Day's Range0.1756 - 0.1950
52 Week Range0.1400 - 0.8900
Volume534,813
Avg. Volume655,554
Market Cap6.486M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023

    DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization (“CDMO”), today provided strategic, financial, and operational updates for the year ended December 31, 2023. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We are executing our plan to augment sales and drive r

  • GlobeNewswire

    Scorpius Holdings Announces Receipt of Filing Delinquency Notification

    Reaffirms commitment to regaining compliance with the NYSE American continued listing standardsDURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC (“NYSE American” or the “Exchange”) continued listing standards (the “Fi

  • GlobeNewswire

    Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

    DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company’s state-of-the-art